Since in-licensing its first drug candidate in December of 2005, SyB L-0501, SymBio has in-licensed three additional drug candidates for development and commercialization in Japan and other Asia Pacific countries. SymBio’s efforts to negotiate with both foreign and domestic bio-ventures and pharmaceutical companies to in-license new product candidates are ongoing. Criteria for the final selection of drug candidates to enter our pipeline is based on three underlying principles:

1. "Medical Need"
2. "Development Duration"
3. "Long-term Profitability"